Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

— Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 —

— Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 —

— VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection —

Excerpt from the Press Release:

SAN CARLOS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the first participants were dosed in the Phase 1/2 clinical study of VAX-24. This clinical proof-of-concept study will evaluate the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD) and pneumonia in adults. The Company expects to announce topline safety, tolerability and immunogenicity results from the Phase 1/2 study by the end of 2022.

“Initiating the VAX-24 Phase 1/2 clinical study is an important step forward in the development of our lead, broad-spectrum PCV candidate, and for our company,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. “We developed VAX-24, using advanced chemistry and our novel XpressCF^TM platform, with the intent to deliver the broadest spectrum PCV to effectively prevent pneumococcal disease and we look forward to announcing the topline safety, tolerability and immunogenicity results from this clinical study by the end of the year.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release